UPDATE : Monday, June 17, 2019
Seoul St. Mary's Hospital certified as obesity metabolic surgery institution by Lee Han-soo 2019-06-17 17:03
SNUH conducts uninsured central serous chorioretinopathy treatment using Lutronic's device by Lee Han-soo 2019-06-17 15:28
Theragen ETEX attends EU genomic conference by Lee Han-soo 2019-06-17 11:36
‘Diabetes, dyslipidemia increases risk of rosacea’ by Lee Han-soo 2019-06-14 17:50
Daewoong to develop hearing loss treatment using ion-channel platform tech by Lee Han-soo 2019-06-14 17:27
Vatech launches new oral scanner by Lee Han-soo 2019-06-14 17:26
Lilly, AbbVie unveil new data for psoriasis treatment at global meet by Lee Han-soo 2019-06-14 14:26
AMC to develop AI-based monitoring system predicting immunotherapies’ side effects by Lee Han-soo 2019-06-13 17:35
Celltrion unveils P3 trial results for rheumatoid biosimilar in Europe by Lee Han-soo 2019-06-13 16:10
GC MS to export cholesterol-gauging device to China by Lee Han-soo 2019-06-13 16:09
Handok to market Medtronic's continuous glucose monitoring device by Lee Han-soo 2019-06-13 11:53
Researchers develop device administering drugs with infrared rays by Lee Han-soo 2019-06-12 16:54
Novo Nordisk’s Saxenda dominates local obesity market by Lee Han-soo 2019-06-12 14:16
[Startups to Watch] 'Noul aims to become major player in eradicating malaria' by Lee Han-soo 2019-06-12 11:01
US expert says Asians less vulnerable to dementia than Europeans by Lee Han-soo 2019-06-11 17:53
[ASCO 2019] Imfinzi 1st IO to report 3-year OS in unresectable stage III NSCLC by Lee Han-soo, KBR Correspondent 2019-06-11 08:00
SCM, T&R to develop tissue regeneration, therapy products by Lee Han-soo 2019-06-10 17:50
Regulator OKs AstraZeneca's Fasenra as additional therapy for severe asthma by Lee Han-soo 2019-06-10 17:10
Hanmi unveils strong pipeline candidates in US diabetes meet by Lee Han-soo 2019-06-10 15:07
[ASCO 2019] 'Ibrance brings hopes to neglected premenopausal breast cancer patients' by Lee Han-soo, KBR Corresponden 2019-06-05 11:33
Back to Top